New Jersey · Nonprofit
INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS OUTCOMES RESEARCH
INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS OUTCOMES RESEARCH (New Jersey) receives grants from 1 organization whose IRS filings report $96,000 to it, the largest being PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA ($96,000). 1 of them have funded it in more than one year.
- Revenue FY2024
- $20M
- Funders on record
- 1
- Grants received
- $96k
- Net assets
- $26M
What International Society for Pharmacoeconomics Outcomes Research does
Mission
The mission of International Society for Pharmacoeconomics Outcomes Research (ispor) is to promote health economics and outcomes research excellence to improve decision making for health globally.
As stated on its FY2024 Form 990.
Program
Ispor is a global, nonprofit scientific and educational society advancing excellence in health economics and outcomes research (heor) to improve healthcare decision-making worldwide.ispor has over 18,000 invidividual and chapter members across more than 100 countries who are involved in healthcare economics and outcomes research, including stakeholders from academia, government, payers, industry, healthcare providers, and patient organizations.ispor fosters the use of health economics and outcomes research for healthcare policy and decision-making worldwide with over 75 regional chapters and nearly 100 student networks across the globe. Through task forces, councils, and special interest groups, ispor also develops consensus guidelines on outcomes research methods and the application of this research in healthcare decisions. The ispor good practices reports are highly cited, expert consensus guidance recommendations that set international standards for heor and its use in healthcare decision making. Other ispor reports and research tools provide guidance on important areas such as hta, health policy, ai and real-world evidence. These resources are widely used with over 1,000,000…
$16,260,823 spent$18,450,488 earned by the program100% of program spending
The program described on its FY2024 Form 990. Program spending in total: $16,260,823.
The organization over time
Each line starts at 100 in 2017, so what you read is the shape rather than the size: 150 means half as much again as 2017, 50 means half. The number beside each label in the key is where it ended. The shaded band is where the middle 50% of its peers' revenue would sit, given their growth.
Balance sheet
Total assets and total liabilities at each year end, in dollars. The largest one-year move in total assets was 2019 to 2020, from $20M to $26M (+29%).
How it's funded, over time
Each bar is one year's revenue split into where it came from, and every bar is the same height — these are shares, not amounts, so a year that raised twice as much looks the same size. Hover a bar for the split.
0% of INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS OUTCOMES RESEARCH’s revenue is contributions — more earned-revenue than three-quarters of its peers (7% for the typical peer).
Surplus & reserves
Operating surplus or deficit each year, and months of liquidity in hand. 2 of the last 8 reported years ran a deficit.
reserve
Leadership and staff
The officers, directors, trustees and key employees listed on each return. Joined and no longer listed compare each filing with the year before, matching people by surname and first initial; a year after a gap, or a roster under three people, has no comparison.
Who funds it, year by year
2018 → 2019: the base held at 1 funder, grant income fell $32k → $30k.
From the IRS filings of INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS OUTCOMES RESEARCH’s funders (the co-funder graph). Association, not causation. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
Where its funders are
INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS OUTCOMES RESEARCH draws 100% of its grant income from funders outside New Jersey, across 1 state in all.
In-state vs out-of-state, by year
Funder states come from each funder’s own filing. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
Against its field
INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS OUTCOMES RESEARCH is better cushioned than half of the 4,580 health nonprofits its size.
this organization peer median middle 50% of peers· 4,580 health nonprofits $10M–$100M, FY2024
Government funding INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS OUTCOMES RESEARCH receives
Grants and contracts to this organization from federal (USASpending) and state checkbooks, reconciled to its EIN. $5k on record.
- Department of Health and Human Services$5k
Federal grants vs contracts are distinguished; state line items keep their reported category. Matched by name + geography (the BMF), so coverage is partial and precision-first.
Organizations like INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS OUTCOMES RESEARCH
Organizations whose mission and program text most resemble this one, by semantic similarity over every organization in the US filings — the closest peers, and often the clearest route to shared or prospective funders.
In New Jersey
Nationally
Read directly from this organization’s own Form 990, as neutral context.
Where the money goes
84% of spending goes to programs.
Governance
Public support
83%
Share of support from the public (Schedule A) — the basis for its public-charity status.
Footprint & structure
Files a return copy in 1 state
Part of a family of 1 related entity
- Ispor Global LLC · disregarded
Screen this organization
A dated, signed PDF of the compliance screen for INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS OUTCOMES RESEARCH: IRS status (Business Master File, Publication 78, auto-revocation), the OFAC sanctions lists, the Internal Revenue Bulletin, and California registration, with the Rev. Proc. 2018-32 §8.01 reliance elements stated element by element. Generated from the current files at the moment you download it.
Screens are triage, not determinations; a source that cannot be read reports not screened, never clear. Screen this nonprofit · How the screen works · on the API as GET /api/screening/{ein}?format=pdf
Questions and answers
- Who funds INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS OUTCOMES RESEARCH?
- INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS OUTCOMES RESEARCH (New Jersey) receives grants from 1 organization whose IRS filings report $96,000 to it, the largest being PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA ($96,000). 1 of them have funded it in more than one year.
- How many funders does INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS OUTCOMES RESEARCH have?
- IRS filings report 1 organization giving $96,000 in grants to INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS OUTCOMES RESEARCH, 1 of which have funded it in more than one year.
- Who is the largest funder of INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS OUTCOMES RESEARCH?
- PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA is the largest funder on record, with $96,000 in grants. The full list of funders is on this page.
- How can an organization like INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS OUTCOMES RESEARCH find more funders?
- Start with the funders already giving here, then look at the foundations that back similar organizations in New Jersey. The funding by cause and by state pages list the largest funders for a given area and how to approach them.
Play a game about who funds International Society for Pharmacoeconomics Outcomes Research →
These figures are read directly from IRS Form 990 / 990-PF e-file XML: this organization’s own return for FY2024 (financials across 2017–2024), and the filings of 1 funders that report grants to it. “On record” means captured in the filings we have parsed — a funder that does not e-file, or whose grant detail is not itemized, will not appear. Filings run roughly 12–24 months behind. Trends on this page end at FY2023, the last fiscal year that has finished arriving; later years are shown and marked, and move no figure. Data on this page was exported October 14, 2026. What this page cannot tell you · view filing